Background: Exosomes and exosome mimetics are used as alternatives to cell therapy. They have shown potential in treating skin disorders by fortifying the skin barrier, mediating angiogenesis, and regulating the immune response while minimizing side effects. Currently, numerous studies have applied exosome therapy to treat atopic dermatitis (AD) caused by a weakened skin barrier and chronic inflammation. Research on exosomes and exosome mimetics represents a promising avenue for tissue regeneration, potentially paving the way for new therapeutic options. However, the efficacy of the therapy remains poorly understood. Also, the potential of exosome mimetics as alternatives to exosomes in skin therapy remains underexplored.
Methods: Here, we reviewed the pathological features and current therapies of AD. Next, we reviewed the application of exosomes and exosome mimetics in regenerative medicine. Finally, we highlighted the therapeutic effects of exosomes based on their cell source and assessed whether exosome mimetics are viable alternatives.
Results And Conclusion: Exosome therapy may treat AD due to its skin regenerative properties, and exosome mimetics may offer an equally effective yet more efficient alternative. Research on exosomes and exosome mimetics represents a promising avenue for tissue regeneration, potentially paving the way for new therapeutic options.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s13770-024-00695-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exosomes and Exosome-Mimetics for Atopic Dermatitis Therapy.
Tissue Eng Regen Med
January 2025
Department of Systems Biotechnology, Chung-Ang University, Anseong-Si, Gyeonggi-Do, 17546, Republic of Korea.
Background: Exosomes and exosome mimetics are used as alternatives to cell therapy. They have shown potential in treating skin disorders by fortifying the skin barrier, mediating angiogenesis, and regulating the immune response while minimizing side effects. Currently, numerous studies have applied exosome therapy to treat atopic dermatitis (AD) caused by a weakened skin barrier and chronic inflammation.
View Article and Find Full Text PDFHydrogel-integrated exosome mimetics derived from osteogenically induced mesenchymal stem cells in spheroid culture enhance bone regeneration.
Biomaterials
January 2025
Division of Oral and Systemic Health Sciences, School of Dentistry, University of California, Los Angeles, CA, 90095, USA; Department of Bioengineering, University of California, Los Angeles, CA, 90095, USA. Electronic address:
Exosomes derived from mesenchymal stem cells (MSCs) offer a promising alternative to traditional cell-based therapies for tissue repair by mitigating risks associated with the transplantation of living cells. However, insufficient osteogenic capacity of exosomes diminishes their potential in bone tissue regeneration. Here, we report novel osteogenically induced exosome mimetics (EMs) integrated into injectable hydrogel carriers for improved bone regeneration.
View Article and Find Full Text PDFPlatelet membrane decorated exosomes enhance targeting efficacy and therapeutic index to alleviate arterial restenosis.
Theranostics
January 2025
Department of Vascular Surgery, Zhongshan Hospital Fudan University, Shanghai, 200032, PR China.
Article Synopsis
- Postinterventional restenosis poses challenges in treating peripheral vascular disease, as current drugs hinder endothelial repair while preventing neointima hyperplasia.
- Stem cell-derived exosomes offer therapeutic benefits by delivering functional microRNAs but face limitations in targeting and tissue uptake in injured vessels.
- To improve efficacy, researchers created platelet-mimetic exosomes (PM-EXOs) that enhance targeting to vascular injuries and promote endothelial repair with minimal side effects, demonstrating significant potential in reducing neointima formation.
Amniotic fluid-derived stem cells: potential factories of natural and mimetic strategies for congenital malformations.
Stem Cell Res Ther
December 2024
Center for Precision Environmental Health, Baylor College of Medicine, One Baylor Plaza, Houston, TX, USA.
Article Synopsis
- Mesenchymal stem cells (MSCs) from gestational tissues are promising for treating congenital malformations but face challenges like invasiveness, prompting the exploration of less risky alternatives like naturally occurring exosomes (EXOs) and their mimics (MIMs) from amniotic fluid-derived MSCs (AF-MSCs).
- The study involved creating MIMs, comparing their properties to EXOs, and evaluating their safety and distribution in a mouse model predisposed to neural tube defects.
- Results indicated that MIMs and EXOs have similar characteristics, with MIMs yielding three times more product, and no adverse effects were found in pregnant mice, making MIMs a promising, minimally invasive therapeutic option.
Phosphatidylserine-incorporated exosome mimetics encapsulating CXCR3 antagonist alleviate osteoporosis.
Adv Funct Mater
September 2024
Division of Oral and Systemic Health Sciences, School of Dentistry, University of California, Los Angeles, CA 90095, USA.
Exosomes derived from mesenchymal stem cells are an active area of research due to their therapeutic potential in treating osteoporosis. To further harness their therapeutic performance in modulating bone resorption, we have equipped exosomes with osteoclast-targeting moieties on their surface as well as chemokine receptor antagonists blocking osteoclast recruitment. Phosphatidylserine (PS), a membrane lipid exerting immunosuppressive and phagocytic signals, was incorporated in the membrane of exosome mimetics (EMs) to achieve a marked affinity for osteoclast precursors and potential anti-resorptive effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!